Compare PRPL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | IMUX |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 75.2M |
| IPO Year | 2015 | 2013 |
| Metric | PRPL | IMUX |
|---|---|---|
| Price | $0.66 | $1.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.00 | ★ $4.80 |
| AVG Volume (30 Days) | 210.4K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.22 | ★ 38.00 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $487,877,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | $1.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.51 |
| 52 Week High | $1.26 | $1.51 |
| Indicator | PRPL | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 51.77 |
| Support Level | $0.66 | $0.61 |
| Resistance Level | $0.84 | $1.17 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 56.25 | 18.18 |
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.